DEAR EDITOR, Recent studies have shown that biological drugs approved for treating
psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the …

Background Obesity is a common comorbidity of psoriasis and can attenuate response to
biologic treatment. Objectives To investigate the efficacy, safety and tolerability of …

Background Plaque psoriasis affects~ 1% of the pediatric population, negatively impacting
quality of life. The efficacy and safety of secukinumab in pediatric patients with moderate to …

Psoriasis is a chronic inflammatory skin disease with high rate of recurrence. New anti-
interleukin-17 (IL-17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove …

Introduction The utilization of biologics in patients with psoriasis with latent tuberculosis
infection (LTBI) has garnered significant attention. Although the tuberculosis (TB) safety …

Introduction Demographic and disease characteristics may impact response to psoriasis
therapies. The objective of this study is to explore the safety and efficacy profile of …

Objective To determine persistence of treatment with secukinumab across its different
indications. Method This is a retrospective descriptive observational study including adult …

Objective To evaluate the effect of secukinumab on radiographic progression through 52
weeks in patients with PsA from the FUTURE 5 study. Methods Patients with active PsA …

Background: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the
Chinese population. Many patients are not well controlled by conventional treatments, thus …

Psoriasis is a chronic inflammatory disease with a multifactorial origin that appears in
patients with genetic predisposition and is induced by environmental factors, and …